|Home | About | Journals | Submit | Contact Us | Français|
Soluble Interleukin-6 receptor (sIL-6R) mediated trans-signaling is an important pro-inflammatory stimulus associated with pathological conditions, such as arthritis, neurodegeneration and inflammatory bowel disease. The sIL-6R is generated proteolytically from its membrane bound form and A Disintegrin And Metalloprotease (ADAM) 10 and 17 were shown to perform ectodomain shedding of the receptor in vitro and in vivo. However, under certain conditions not all sIL-6R could be assigned to ADAM10/17 activity. Here, we demonstrate that the IL-6R is a shedding substrate of soluble meprin α and membrane bound meprin β, resulting in bioactive sIL-6R that is capable of inducing IL-6 trans-signaling. We determined cleavage within the N-terminal part of the IL-6R stalk region, distinct from the cleavage site reported for ADAM10/17. Interestingly, meprin β can be shed from the cell surface by ADAM10/17 and the observation that soluble meprin β is not capable of shedding the IL-6R suggests a regulatory mechanism towards trans-signaling. Additionally, we observed a significant negative correlation of meprin β expression and IL-6R levels on human granulocytes, providing evidence for in vivo function of this proteolytic interaction.
The metalloproteases meprin α and meprin β belong to the astacin family of zinc endopeptidases and the metzincin superfamily. They are evolutionarily related to Matrix Metalloproteases (MMPs) and A Disintegrin And Metalloproteases (ADAMs)1, but possess unique structural and functional properties when compared to other metalloproteases2. Constitutive furin-mediated cleavage of meprin α along the secretory pathway results in the release of the enzyme into the extracellular space3 where it undergoes non-covalent oligomerization and can build huge complexes to form the largest secreted protease known to date4,5. In contrast, meprin β is found primarily tethered to the cell membrane but, under certain conditions, may be shed from the surface by ADAM10 or ADAM176,7. Many transmembrane proteins have been identified as substrates for ADAMs including Notch, pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and its receptor TNFRI, adhesion molecules and the APP8,9,10,11,12,13,14,15,16. Interestingly, meprins were also shown to cleave ligands of the epidermal growth factor receptor (EGFR)17, as well as APP18,19 pointing to a partially shared substrate-repertoire of ADAMs and meprins.
Additionally, ADAM10/17 can cleave the membrane-bound interleukin-6 receptor (IL-6R)20,21,22,23,24, which plays a critical role in the initiation and propagation of inflammation25,26,27. The IL-6R is expressed in a restricted subset of cell types28,29,30,31 and can signal in two different manners, namely the predominantly pro-inflammatory trans-signaling via sIL-6R32 or the more regenerative classical signaling via membrane-bound IL-6R33,34.
There is evidence that highlight the potential of meprins to modulate the immune environment by cleaving mucin 2 important for intestinal mucus detachment35, processing bacterial proteins therby preventing invasion36, and modulating the activity of pro-inflammatory cytokines, such as interleukins (ILs), including IL-1β and IL-1837,38,39 as well as IL-640, which are released in response to tissue injury and inflammation. This is further supported by distinct immunological phenotypes observed in meprin α and meprin β deficient mice41,42,43. For instance, meprin α knock-out animals showed more severe inflammation and intestinal injury in a DSS (dextran sodium sulfate)-induced colitis model compared to wild-type animals44, which is comparable to that observed in studies with significantly reduced expression of ADAM17 in mice45.
Until now, ADAM10 and ADAM17 are the only metalloproteases accredited with the ability to cleave the IL-6R20,21,22,23,24,46. However, the initial cleavage site identified by Müllberg and colleagues between Gln357 and Asp35846 with a negatively charged residue at the P1 prime (P1’) position does not coherent with predicted sequence preference for ADAMs that appear to favor more hydrophobic amino acids such as valine and leucine47. Indeed, recombinant ADAM17 cleaved an IL-6R peptide comprising a part of the stalk region, situated two residues N-terminal of QD between Pro355 and Val35648. This cleavage site was further substantiated by molecular modelling49. Interestingly, meprin α and meprin β were found to exhibit a striking preference for negatively charged amino acids at the P1’ position50, which correlates with the previously observed cleavage site in the IL-6R46. Here, we demonstrate that the IL-6R is indeed cleaved by soluble meprin α as well as membrane-bound meprin β. Ectodomain shedding of the IL-6R by meprins results in the generation of biologically active soluble IL-6R capable of inducing IL-6 trans-signaling.
In 1994 Müllberg and colleagues identified a cleavage site within the stalk region of the IL-6R between Gln357 and Asp358 (Fig. 1A), which was assigned to a shedding protease’s activity, most likely ADAM1746. However, it has been demonstrated recently that negatively charged amino acid residues at the P1’ position are disliked by ADAM1747, but highly favoured by the metalloproteases meprin α and meprin β (Fig. 1B,C)50, which were further analyzed in our study. We therefore created a peptide spanning this particular region within the stalk of the IL-6R (Fig. 1A). The use of two different mass spectrometric technologies (LC-ESI MS and MALDI-MS) in parallel enabled identification of cleavage sites within the peptide (Fig. 1D,E). These results clearly showed that the peptide was cleaved, predominantly between amino acid residues glutamine and aspartate, after incubation with recombinant soluble meprin α or meprin β (Fig. 1F), with slightly faster kinetics of peptide digestion for meprin β (data not shown). These results prompted us to further analyze IL-6R cleavage by meprins in a cell culture model.
To avoid constitutive shedding of the IL-6R by ADAM proteases before meprin treatment as well as other protease-protease-interactions, IL-6R was transiently overexpressed in HEK cells deficient for ADAM10 and ADAM1749. Addition of active soluble recombinant meprin α led to a concentration (Fig. 2A) and time dependent (Fig. 2B) increase highlighted through the abundance of a cleavage fragment of the IL-6R of approximately 50kDa. Surprisingly, this was not the case after application of active recombinant soluble meprin β (Fig. 2C). Interestingly, we observed that transient transfection of IL-6R resulted in the release of a probable full-length form of the IL-6R of about 100kDa into the supernatant (Fig. 2A–C). To verify this we used an antibody directed against the C-terminus of the IL-6R that exclusively detects the full-length IL-6R. Employing this antibody, we again analyzed cell culture supernatants from IL-6R transfected cells in the presence or absence of meprin α and indeed found the full-length version of the IL-6R in the supernatant which increased over time, whereas the meprin α generated fragment was not detected (Fig. 2D). To further evaluate the cleavage of the IL-6R by meprins we then transfected IL-6R overexpressing cells with full-length meprin α or meprin β. In these cells, not only meprin α but also membrane bound meprin β were both capable of cleaving the IL-6R to release a soluble fragment of about 50kDa (Fig. 2E). Thus, we can state that soluble meprin α and membrane bound but not soluble meprin β cleave the IL-6R (Fig. 2F).
To further demonstrate in a cellular system that the meprin α and meprin β mediated cleavage of the IL-6R takes place between Gln357 and Asp358, as observed in the peptide cleavage assay (Fig. 1), two mutants of the IL-6R were analyzed (Fig. 3A; QD in red) that were previously reported in46. The QD >QR mutant was analyzed, due to the fact that meprins strongly dislike positively charged amino acids around the scissile bond51. Surprisingly, both mutants were still shed after co-transfection with meprin β (Fig. 3B). Thus, we analyzed the structural properties of membrane bound meprin β based on the crystal structure of the ectodomain52 and fitted it with a model of the full-length IL-6R53 (Fig. 3C). We found that the orientation of the catalytic domain of meprin β requires a loop within the stalk region of the IL-6R of about 20–25 amino acids to obtain access to the active site cleft, where hydrolysis of a peptide bond occurs. It turned out that Gln357 and Asp358 are in too close proximity to the cell surface, which excludes cleavage of the IL-6R by meprin β at this particular site (Fig. 3C). Analysing the stalk region of the IL-6R revealed several other negatively charged glutamate and aspartate residues, which may be cleaved by meprin α and meprin β (Fig. 3C,D). To narrow down the cleavage site, four additional mutants of the IL-6R lacking various parts of the stalk region were analyzed (Fig. 3D). The first two deletion mutants, lacking amino acids Ala333-Asn342 and Ile343-Thr352 respectively (Fig. 3D), were still cleaved by co-transfected meprin β resulting in a single soluble fragment of the IL-6R (Fig. 3E). In the third mutant almost the entire stalk region spanning amino acids Glu317-Thr352, was deleted, except the last 14 residues including the QD motif. Here, no sIL-6R fragment could be detected in the supernatant upon co-transfection with meprin β indicating that shedding was completely abolished (Fig. 3F). These findings clearly exclude Gln357 and Asp358 as the cleavage site used by meprin β. To additionally validate this finding, ten amino acids were deleted including the QD motive (Ser353-Val362). This mutant was again shed by the co-expressed meprin β to release a fragment of about 50kDa.
However, our mutation experiments indicate that the sIL-6R fragment generated by meprin β is smaller than the one produced by ADAM17. To further investigate this, we co-transfected ADAM10/17 double-deficient HEK cells with the IL-6R and meprin β or ADAM17. In the cell supernatants a smaller sIL-6R fragment was detected when meprin β was co-expressed (~50kDa) compared to ADAM17 co-expression (~70kDa) (Fig. 3G). Altogether this indicates a cleavage site N-terminal to the one used by ADAM17. We assume that the large difference in molecular weight between meprin and ADAM17 generated sIL-6R is due to the difference in length of the remaining stalk region and particularly due the absence or presence of glycosylated Asn350, respectively, as indicated in Fig. 3D46.
We have shown that meprin α and meprin β proteolytically release sIL-6R from the cell surface. However, we also observed constitutive secretion of full-length IL-6R into the media, which was independent of meprins (Fig. 2A–C). This was proven by an antibody that recognizes an epitope within the intracellular C-terminus of IL-6R (CT-Ab) that only detects the upper band of about 100kDa corresponding to the full-length receptor and not the proteolytically shed sIL-6R at 50kDa (Fig. 2D). It is likely that this higher molecular weight form of the IL-6R is secreted in microvesicles, similar to those observed in human serum54. Therefore, we employed ultracentrifugation to eliminate microvesicles55 that may contain full-length IL-6R from cell media that may interfere with functional assays of the sIL-6R carried out in further experiments. After removal of microvesicles, only the cleaved form of the IL-6R was detectable in cell culture supernatants (Fig. 4A). This purified fraction was used for functional assays in a murine B-cell line (Ba/F3)56 stably transfected with the signal transducing receptor gp13057,58. Cell culture supernatants of A10/17 dKO HEK cells were generated after transfection with the IL-6R and then either incubated with recombinant meprin α or co-transfected with meprin β. In both cases a significant increase in the proliferation rate of the Ba/F3-gp130 cells dependent on IL-6 was detectable (Fig. 4B,C), indicating that meprin α and meprin β produce bioactive sIL-6R. To proof that only meprin generated sIL-6R is mediating Ba/F3 cell proliferation, we additionally applied Tocilizumab, which blocks the IL-6 binding site of the α receptor, to conditioned media from meprin α treated HEK cells, overexpressing the IL-6R. Indeed, proliferation of Ba/F3-gp130 cells was completely abolished in the presence of the therapeutic (Fig. 4D).
The IL-6R is highly expressed on immune cells of the human body29. Meprin β was shown to play a role during inflammatory processes, such as inflammatory bowel disease and nephritis, and therefore its expression on the surface of immune cells was suggested59,60. To analyze this with regard to IL-6R shedding, we took human blood samples from 11 healthy donors and analyzed the meprin β and IL-6R level on the cell surface by flow cytometry (Fig. 4E). We found a strong signal for meprin β on granulocytes that was clearly different from the pre-immune serum stained control (Fig. 4F). Interestingly, we observed a highly significant negative correlation between the meprin β and IL-6R surface levels. The more meprin β was detected the less IL-6R was present at the cell surface of granulocytes (Fig. 4G). This finding strongly points towards an in vivo cleavage of the IL-6R by meprin β under physiological conditions, at least on granulocytes. For T-cells, ADAM10/17 were described as the major sheddases of the IL-6R in vivo61,62. Therefore, we additionally analyzed these cells and could detect only very little meprin β at the cell surface, when compared to granulocytes (Fig. 4H). Regarding the IL-6R surface levels, however, there were differences seen between the 11 blood samples (Fig. 4G), which are in the same range as seen on granulocytes. However, these IL-6R levels did not correlate with the little amounts of meprin β detectable on T-cells, indicating other receptor shedding activities than that of meprin β (Fig. 4I).
The IL-6R is an important signal transducer that can act via two mechanisms; classic signaling on the same cell and trans-signaling after proteolytic release acting on other cells that do not express the IL-6R63,64 (Fig. 5). Previously ADAM10 and ADAM17 were described to be the major shedding enzymes of the IL-6R23,46,61,65. However, some studies reported in literature regarding the cleavage site specificity of ADAM10/17 and the constitutive sIL-6R levels in serum gave rise to speculation of other proteases additionally involved in IL-6R shedding47,54.
Here, we describe meprin α and meprin β as two novel metalloproteases that are capable of shedding the IL-6R and thereby releasing biologically active sIL-6R fragments from the cell surface. We identified meprin α as the first soluble metalloprotease that can shed the IL-6R. Interestingly, meprin α was previously shown to cleave and release some ligands of the EGFR17, additionally demonstrating a partially overlapping substrate repertoire with ADAM10/17. On the other hand, meprin β membrane tethering appears to be a prerequisite for IL-6R shedding, because the soluble protease did not result in receptor cleavage. A similar observation was made for the APP where only membrane bound and not shed meprin β exhibits β-secretase activity18,66. This points towards strict regulation of meprin β activity at the cell surface as its shedding completely switches its preference towards certain substrates. Interestingly, ADAM10 and ADAM17 were previously identified as sheddases for meprin β6, indicating a complex scenario of cellular protease-protease-interactions and substrate cleavage competition in the regulation of the protease web67,68.
As the cleavage site within the IL-6R stalk region published by Müllberg and colleagues46 between Gln357 and Asp358 (QD motif) fits nicely to the specificity of both meprin metalloproteases50 and not to ADAM10/1747, we addressed cleavage of the IL-6R by meprins in detail. Surprisingly, we found that this particular QD motif is not used by meprin α and meprin β for the generation of sIL-6R. Instead, other negatively charged amino acids in the very N-terminal region of the IL-6R stalk are most likely cleaved by meprins supported by different IL-6R stalk deletion mutants. Additionally, the cleavage fragments of the IL-6R generated by meprins appeared to have a molecular weight approximately 20kDa less than those released by ADAM10/17. This remarkable difference in size cannot only be explained by the different number of amino acids in the remaining stalk. This indicates cleavage by meprins N-terminal of the known N-glycosylation site (Asn350), which is still present in the ADAM10/17 mediated cleavage product46. Indeed, deglycosylation of ADAM17 and meprins generated sIL-6R revealed a shift in molecular weight towards a 35kDa band (data not shown). Similar observations for ADAM17 mediated sIL-6R were previously published by Müllberg and colleagues46. We assume that the triple D-motif (D339DD341) and the two glutamate residues Glu324 and Glu326 are in a good distance to the membrane to be processed by meprin metalloproteases. Deduced from the crystal structure of meprin β52 and based on our model of the membrane bound enzyme in complex with the IL-6R, we conclude that the minimum number of amino acids adjacent to the membrane region is 20–25 that would allow correct orientation of the scissile bond within the active site cleft of meprin β. This explains why the QD motif is cleaved by meprin β only in the peptide assay and not in the full-length IL-6R as it is only eight amino acids apart from the membrane helix. Furthermore, cleavage of the IL-6R by ADAM10/17 between PV or QD, as well as the localization of cleavage sites in other known substrates49,69, suggests a structural conformation of these ADAMs where the catalytic domain is in very close proximity to the cell surface, as seen for meprin β, but with 180° rotation of the active site cleft.
We could show that the sIL-6R fragment that is produced by meprins has full bioactivity as demonstrated in the Ba/F3-gp130 cell proliferation assay56. This finding is in line with structural information on the IL-6R, IL-6 and gp130 complex as the IL-6R stalk is not involved in complex formation.
The in vivo function of ADAM10/17 mediated shedding of the IL-6R from activated immune cells, for instance T-cells and macrophages, has been demonstrated multiple times70. Nevertheless, IL-6R shedding under certain conditions cannot be clearly assigned to ADAM10/17 activity54. Thus, meprins may contribute to the release of sIL-6R under conditions where ADAMs do not play a major role. Indeed, we observed a significant correlation of meprin β and IL-6R on the surface of granulocytes, clearly showing that high expression of the protease is associated with low receptor levels. Thus, meprin β could determine the amount of IL-6R on granulocytes that is delivered to a site of inflammation and consequently may determine the amount of IL-6R that can be shed by ADAM proteases after immune cell activation. On the other hand, ADAM10/17 were suggested to be the relevant sheddase of the IL-6R on T-cells in vivo61,62. In line with this finding we did not observe a correlation between meprin β surface expression and the IL-6R on T-cells.
In summary, we describe two new sheddases for the IL-6R, namely meprin α and meprin β, which use a different cleavage site in the stalk region of the receptor, when compared to the well-known sheddases ADAM10 and ADAM17. Both meprins generate bioactive sIL-6R capable of trans-signaling. More importantly, we found a negative correlation between meprin β and IL-6R levels on the surface of human granulocytes (summarized in Fig. 5). Thus, the pro-inflammatory activity of meprin metalloproteases may be considered for the treatment of associated conditions, such as Kawasaki disease71 or inflammatory bowel disease44.
Reagents for molecular biology and protein standards were obtained from Fermentas (St. Leon-Rot, Germany). BCA protein assay kit and Western blotting reagents were from Pierce (Rockford, USA) and Amersham (Little Chalfont, United Kingdom). Complete® protease inhibitor was purchased from Roche (Mannheim, Germany). Media for common cell culture was acquired from Thermo Fisher Scientific (Bremen, Germany). If not otherwise mentioned, all other chemicals were purchased from Sigma-Aldrich (Steinheim, Germany).
Primary antibodies included rabbit-anti-CT-Ab (#SC661; Santa Cruz), rabbit-anti-actin (A2066, Sigma-Aldrich, Steinheim, Germany), rabbit-anti-GAPDH (14C10, Cell Signaling, Frankfurt am Main, Germany), rabbit-anti-meprin α (self-designed at Pineda, Berlin, Germany), and rabbit-anti-meprin β72, mouse-anti-human-IL-6R (4–11)73 and goat-anti-mouse-IL-6R (AF1830, R&D systems, Wiesbaden-Nordenstadt, Germany). Secondary antibodies used were Alexa Fluor 488, biotinylated antibodies (Molecular Probes, Eugene, USA) and peroxidase conjugated antibodies (Dianova, Hamburg, Germany).
Expression and purification of recombinant meprin α and -β was performed as previously described4,74. Briefly, proteins were heterologously expressed via baculovirus amplification in insect cells using the Bac-to-Bac system (Gibco, Thermo Fisher Scientific) according to the manufacturer’s instructions. Recombinant meprins were diluted in culture media devoid of fetal calf serum and subsequently incubation with cells at indicated concentrations for 2–24hours.
344μM synthetic IL6R peptide (ATSLPVQDSSSVPLP) was incubated with 5nM recombinant meprin α or meprin β in 20mM HEPES and incubated for 2h at 37°C. Reaction was stopped by addition of 0.1% trifluoroacetic acid (TFA) in ddH2O. Reverse high performance liquid chromatography (HPLC) analysis was performed using a gradient from 2% acetonitrile/0.1% TFA/H2O up to 60% acetonitrile/0.1% TFA/H2O in 38minutes. All peak fractions were collected and analyzed by MALDI MS. Two hundred μL of each fraction collected by HPLC was concentrated in a vacuum centrifuge and redissolved in 20μL of 3% acetonitrile, 0.1% trifluoroacetic acid. Samples were mixed with matrix (3mg/mL α-cyano-4-hydroxycinnamic acid dissolved in 70% acetonitrile/0.1% trifluoroacetic acid) and spotted on a 384-spot target plate and measured in positive ion mode using an AB Sciex 5800 MALDI TOF/TOF MS (AB Sciex, Darmstadt, Germany). The matrix cluster (m/z of 877.034) was used for internal calibration of the MS spectra.
In addition, several fractions were analyzed by LC-ESI MS using a nano-HPLC system (UltiMate 3000, Dionex, Idstein, Germany) encompassing a trapping column (Acclaim PepMap 100; 100Å pore and 5μm particle size, 300μm i.d.×5mm) and an analytical reversed-phase C18 column (PepMap; 100Å pore and 3μm particle size, 75μm i.d.×15cm) that was coupled online to the mass spectrometer through a nanospray ion source (New Objective, Woburn, MA). Peptides were separated using a linear gradient at a flow rate of 300nL/min. MS analysis was performed on an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Full MS scans (300–2000m/z) were recorded at 60,000 mass resolutions. Following a full MS scan the five most intense signals were subjected to HCD fragmentation using a normalized collision energy of 40 and a dynamic exclusion of 5s. Lock mass (445.120025) was used for data acquired in MS mode. MSMS spectra in both MALDI MS and LC-ESI MS were annotated manually.
Generation of CRISPR/Cas9 mediated knock-out of ADAM10/17 in HEK cells is described in49. Deficiency of ADAM10/17 was confirmed via activity assays, FACS and Western blotting.
Cells were maintained in 5% CO2 atmosphere at 37°C in Dulbecco’s Modified Eagle’s Medium (Thermo Fischer, Darmstadt Germany) supplemented with 10% (v/v) Fetal bovine serum (FCS) as well as penicillin/streptomycin (Thermo Fischer, Darmstadt Germany). For treatment of cells with recombinant protein, 48hours post transfection, cells were cultured without FCS prior to analysis due to the meprin-inhibiting properties serum75. For co-transfection experiments cells were cultured 24hours without FCS.
The biological activity of soluble IL-6R was analyzed as described previously76. In brief, equal amounts of Ba/F3-gp130 cells were incubated with 50% conditioned cell culture supernatant and/or recombinant proteins as indicated in a final volume of 100μl per well in a 96 well plate. Cell viability was determined using the Cell Titer Blue Cell viability assay reagent (Promega, Karlsruhe, Germany) according to the manufacturer’s instructions. To block IL-6 signaling Tocilizumab was added at a concentration of 10μg/ml.
Expression plasmids containing the cDNA encoding the human IL-6R and IL-6R variants with deletions within the stalk region have been described previously77.
Surface expression of meprin β and IL-6R was analyzed on human blood cells. Therefore human heparinized whole blood samples were blocked with Fc block (Human TruStain FcX, BioLegend) diluted 1:100 in FACS buffer (1% BSA [w/vol] in PBS) for 15minutes and subsequently stained with either anti-meprin β (hEcto1, polyclonal rabbit against human meprin β ectodomain, Pineda) or the pre-immune serum as a negative control, diluted 1:500 in FACS buffer for 1hour, followed by 30minutes incubation with the secondary antibody, goat anti-rabbit Alexa Fluor 488 conjugate (Life Technologies), diluted 1:300. For detection of IL-6R and CD3, cells were stained with either anti-IL6R-APC (clone UV4, BioLegend) or the corresponding isotype control (mouse IgG1, κ BioLegend) or anti-CD3-FITC (clone UCHT1, Biolegend) diluted 1:100. All incubations were carried out at 4°C. Lysis of erythrocytes was performed in RBC Lysis/Fixation Solution (BioLegend) subsequent to staining procedure. Labeled cells were analyzed utilizing a FACS Canto II flow cytometer (BD Biosciences) and data were evaluated with FlowJo (Tree Star) software. T cells were defined as CD3+whereas granulocytes were gated by FSC/SSC as SSChigh.
All individuals underwent a written, informed-consent process approved by the ethics commission of the Medical Faculty of Kiel University (A 102/14).
After removal of supernatant media, cells were scraped in ice-cold PBS, before centrifugation at 5,000rpm for 10minutes. Supernatants were cleared via centrifugation at 5,000rpm for 10minutes before Concanavalin A (ConA) immunoprecipitation or acid precipitation. To exclude the full-length receptor on microvesicles in the supernatant, serial centrifugation at 4,000rpm for 3minutes, at 13,000rpm for 15minutes and ultracentrifugation at 55,000rpm for 2hours was performed. Cells were lysed in PBS containing 1% triton-X with complete® protease inhibitor. Fifty μl of (ConA) beads (GE Healthcare, Freiburg, Germany) was washed once in PBS and added to 1ml of media for precipitation of all glycosylated proteins. The bead/media mixture was incubated overnight at 4°C before centrifugation at 5,000rpm for 5minutes. The supernatant was discarded and the pellet heated to 95°C for 10minutes in 3 x Laemmli buffer78 before loading on an SDS-PAGE gel.
Trichloroacetic acid (TCA) precipitation of soluble proteins was carried out as follows. Centrifuged media (1ml) was mixed in a 1:1 ratio with 20% TCA solution w/v before incubation on ice for 30minutes, then centrifuged at 14,000rpm for 20minutes at 4°C. The pellet was subsequently washed with 350μl acetone. After inverting several times, the pellet was centrifuged for 15minutes at 14,000rpm at 4°C. The supernatant was decanted off and the pellet allowed to dry overnight at room temperature. Resuspension of the pellet via 20μl 3 x Laemmli buffer was achieved by repeated pipetting and heating the sample to 95°C for 10minutes, which was followed by SDS-PAGE and immunoblot analysis.
All values are expressed as the mean±SEM. Difference among mean values were analyzed via one-way ANOVA followed by Tukey post-Hoc test or the linear regression was analyzed using GraphPad Prism 5. In all analyses the null hypothesis was rejected at p<0.05.
Molecular modeling was performed using Modeller79. As a basis the meprin β and APP structural model was used52. All molecular imaging was performed using UCSF Chimera80. All methods were performed in accordance with the relevant guidelines and regulations of the University of Kiel.
How to cite this article: Arnold, P. et al. Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling. Sci. Rep. 7, 44053; doi: 10.1038/srep44053 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In memory of Erwin E. Sterchi (†) and his great achievements on protease research. We thank Inez Götting for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) grant BE4086/5-1 (to CBP), SFB 654 (Plasticity and Sleep; project C05), SFB 974 (Liver Damage and Regeneration; project A12), and SFB 877 (Proteolysis as a Regulatory Event in Pathophysiology, projects A1, A9, A10, and Z2).
The authors declare no competing financial interests.
Author Contributions P.A. and C.B.P. conceived and coordinated the study and wrote the manuscript. S.R.J., B.R., J.S., R.L., and C.G. provided materials and edited the paper. P.A., I.B., M.R., U.P., N.S., F.S., R.W., J.S., J.L., T.K., A.T., C.G., and C.B.P. performed experiments and/or analyzed the data.